Machine-readable JSON: https://agents.comepass.xyz/api/v1/kr-suppliers/2048177696

wonkangpharm (주식회사원강팜)

Business Registration No.: 2048177696 | Unlisted Corporate Supplier

English Name (KONEPS / DART)wonkangpharm
Korean Legal Name주식회사원강팜
Business Registration No.2048177696
Established Date2003-04-28
Region서울특별시 관악구
Address (KO)서울특별시 관악구 조원로 117 (신림동)
HomepageN/A
Manufacturer Classificationsupplier (공급)
Reported Employees13 (Self-reported employee count at Korea ON-Line E-Procurement System (KONEPS) registration; may differ from National Pension Service (L1) subscriber counts.)
source_urlhttps://www.g2b.go.kr
verified_at2026-11-02T04:36:11.608Z

Public procurement (last 12 months)

Contracts first signed in the last 12 months.

The 12-month window is by original contract signing date: it covers contracts first signed in the period, and excludes amendments registered in the period to contracts signed earlier. Amounts are in KRW from Korea's Public Procurement Service (KONEPS). The 12-month total counts sole contracts in full and joint contracts by the supplier's share; joint contracts without a published share are counted but not summed. Multi-year contracts count only the current-period amount. Unit-price (framework) contracts are reported separately because their values are ceilings, not spend.

Aggregation Period2025-11-01 to 2026-10-31 (basis: original_signed_date)
12-Month Procurement AmountKRW 3,682,771,000
12-Month Contract Count12 (Joint contracts: 0)
Unit-Price (Framework) Contracts (Reported Separately)7 contracts | Ceiling: KRW 2,311,539,050
Procurement Sourcehttps://www.g2b.go.kr (verified: 2026-11-02T04:36:11.608Z)

By Procurement Category

CategoryContracts12M Counted Amount (KRW)
Goods (물품)12KRW 3,682,771,000
Construction (공사)0KRW 0
Services (용역)0KRW 0
Foreign Procurement (외자)0KRW 0

By Contract Type

Contract TypeContractsSupplier Share / Current Amount (KRW)Total Contract Ceiling / Multi-year Total (KRW)
Lump-sum / Standard (총액·일반)5KRW 3,682,771,000KRW 0
Multi-year / Continuing (장기·계속비)0KRW 0KRW 0
Unit-price / Framework Ceiling (단가·제3자단가 — excluded from 12M total)7KRW 2,311,539,050KRW 0
Unclassified / Zero-amount (기타)0KRW 0KRW 0

Top 5 Government Buyers

Buyer (Korean Legal Name)Agency CodeContracts12M Amount (KRW)
국민건강보험공단 일산병원Z0043423KRW 2,081,313,390
근로복지공단본부Z0049051KRW 1,585,292,410
서울특별시 동부병원61101643KRW 16,165,200
서울특별시 서남병원ZT001122KRW 0
서울특별시서울의료원B5527491KRW 0

Recent Contracts (up to 12)

Signed DateContract No. (KONEPS)Contract Title (KO)Category / TypeBuyer (KO)Contract Amount (KRW)Participation
2026-08-25 (chg: 2026-10-22) R26TA02160951 중앙수급 의약품(4그룹) goods / lump_sum 근로복지공단본부 KRW 1,585,292,410 Sole (100%)
2026-07-01 R26TA02020380 정기 의약품 공급(단가) 계약 goods / lump_sum 국민건강보험공단 일산병원 KRW 1,900,490,480 Sole (100%)
2026-04-28 R26TA01808451 도타렘주 외 1종 단가 계약 goods / unit_price 서울특별시 동부병원 KRW 18,927,050 Sole (100%)
2026-04-20 R26TA01800335 2026년 의약품 옵티레이320주사 500ml 외 1종 단가계약 goods / unit_price 서울특별시 서남병원 KRW 8,933,480 Sole (100%)
2026-02-10 R26TA01458411 방사선재료 2종 구매 계약 goods / lump_sum 서울특별시 동부병원 KRW 16,165,200 Sole (100%)
2026-01-27 R26TA01389922 파미레이370주 단가 계약 goods / unit_price 서울특별시 동부병원 KRW 16,524,000 Sole (100%)
2025-12-31 R25TA01290890 2026년도 정기 진료재료 공급(단가) 계약 goods / lump_sum 국민건강보험공단 일산병원 KRW 13,802,910 Sole (100%)
2025-12-30 R25TA01295790 2025년 의약품(통합구매 유찰그룹) 단가계약(17그룹) goods / unit_price 서울특별시서울의료원 KRW 1,302,521,750 Sole (100%)
2025-12-19 R25TA01208425 2026년 성남시의료원 의약품(1~8그룹 단가계약)구매(7그룹) goods / unit_price 성남시의료원 KRW 300,894,230 Sole (100%)
2025-12-03 R25TA01156493 2026년 경찰병원 의약품 연간단가 계약(퇴장방지) goods / unit_price 경찰청 경찰병원 KRW 275,983,600 Sole (100%)
2025-11-26 R25TA01142034 2025년 의약품 제네틱스 350 주사 100ml 외 13종 단가계약 goods / unit_price 서울특별시 서남병원 KRW 387,754,940 Sole (100%)
2025-11-25 R25TA01127121 의약품 공급(단가) 계약 goods / lump_sum 국민건강보험공단 일산병원 KRW 167,020,000 Sole (100%)

Source & Disclaimer

source_url: https://www.g2b.go.kr | verified_at: 2026-11-02T04:36:11.608Z

Data from Korea's Public Procurement Service (KONEPS contract and supplier records) via data.go.kr. Corporate suppliers only; sole proprietors are excluded. Not investment advice.